Main Uses of Butilhioscina

Butilhioscina, also known as hyoscine butylbromide, is primarily used to relieve symptoms associated with spasms of the smooth muscles in the gastrointestinal, biliary, and genitourinary tracts. It is classified as an antispasmodic agent designed to act specifically on the involuntary muscles of the internal organs.

Gastrointestinal Conditions

The most common application of this medication is the treatment of abdominal cramps and discomfort. It is frequently used for:

• Irritable Bowel Syndrome (IBS): Helping to manage the acute bouts of abdominal pain and cramping associated with this chronic condition.
• General Gastrointestinal Spasms: Alleviating pain caused by excessive contractions of the stomach or intestines.
• Biliary Colic: Addressing spasms in the bile ducts that can cause intense pain.

Genitourinary Conditions

Butilhioscina is also utilized to treat spasms occurring in the urinary system and the reproductive tract, including:

• Bladder Spasms: Reducing involuntary contractions of the bladder wall.
• Renal Colic: Managing the pain resulting from spasms in the ureters, often associated with kidney stones.
• Menstrual Cramps (Dysmenorrhea): Relieving the smooth muscle contractions of the uterus during menstruation.

Benefits and Mechanism of Action

The primary benefit of Butilhioscina is its targeted approach to pain relief. Unlike general analgesics that mask pain signals throughout the body, this medication works by relaxing the specific muscles that are causing the discomfort.

Targeted Relief

Because it is a quaternary ammonium derivative, Butilhioscina does not easily cross the blood-brain barrier. This means its action is largely confined to the peripheral nervous system, specifically the parasympathetic ganglia of the internal organs. This localized action helps reduce the incidence of central nervous system side effects while providing effective relief at the source of the spasm.

Rapid Symptom Management

When used for acute cramping, the medication helps to restore normal muscle movement and pressure within the affected organs. This relaxation leads to a significant reduction in the intensity of sharp, localized pain, allowing for improved comfort during episodes of digestive or urinary distress.

Eligibility for Butilhioscina (Hyoscine Butylbromide) is strictly defined by regulatory guidelines, restricting use based on pre-existing conditions and population characteristics. The medicine is contraindicated and must not be used by patients with Myasthenia Gravis, narrow-angle glaucoma (untreated), megacolon, paralytic or obstructive ileus, or mechanical stenosis of the gastrointestinal tract. Patients with known hypersensitivity to the drug or its excipients are also non-eligible.

The parenteral (injection) form carries additional restrictions, being contraindicated in patients with tachycardia, cardiac failure, and prostatic hypertrophy with urinary retention. Intramuscular injection is prohibited for individuals receiving anticoagulants.

Use is not recommended in several populations where safety data is limited: This includes children under 6 years of age for the oral tablets and individuals who are pregnant or breastfeeding. Caution is formally required for patients susceptible to urinary outlet obstructions, those prone to tachyarrhythmias, and patients with pyrexia (fever). For older adults, no specific restrictions are noted, though data sufficiency is limited.

Butilhioscina (hyoscine butylbromide) interaction information is derived from its function as a peripherally acting anticholinergic agent. The interactions primarily involve pharmacodynamic reinforcement and opposition with other medicines. Co-administration with other substances possessing anticholinergic properties—which include tri- and tetracyclic antidepressants, certain antihistamines, and some antipsychotics (e.g., phenothiazines)—may intensify the overall parasympatholytic effect.

Conversely, the co-use of Dopamine Antagonists, such as metoclopramide or domperidone, results in a diminution of the drug's intended gastrointestinal effects due to their opposing actions on motility. The chronotropic action of beta-adrenergic agents may also be enhanced.

The drug's effect on intestinal motility can indirectly affect the absorption of other therapies. Specifically, Butilhioscina can cause a delay in the systemic absorption of other orally administered medications. To avoid reducing the efficacy of the spasmolytic itself, official guidelines state that antacids or adsorbent anti-diarrheals should be administered at least one hour prior to Butilhioscina.

A critical restriction exists based on the administration route: the intramuscular injection route is contraindicated in patients receiving anticoagulant drugs (e.g., Warfarin). This mandatory restriction is in place due to the documented risk of intramuscular hematoma. Official warnings also advise against the co-use of alcohol, as it may increase the risk of side effects such as drowsiness.

Butilehioscina (Hyoscine butylbromide) is a quaternary ammonium antimuscarinic agent whose action is primarily confined to the periphery, targeting specific signaling pathways outside the central nervous system, particularly in the smooth muscle of the visceral organs.

---

Muscarinic Receptor Antagonism

This domain involves the drug's high affinity for muscarinic acetylcholine receptors (mainly M2 and M3 subtypes) located on visceral smooth muscle cells. Butilehioscina competitively binds to these receptors, thereby blocking the action of the excitatory neurotransmitter acetylcholine. This antagonistic interaction suppresses the signaling sequence that promotes muscle contraction, leading to the inhibition of smooth muscle contraction.

---

Modulation of Parasympathetic Signaling

The drug engages mechanisms that regulate the parasympathetic nervous system signaling within the target organs. By blocking muscarinic receptors, it interrupts the efferent pathway responsible for controlling increased gastrointestinal or genitourinary motility and secretion. This interference modifies the downstream signaling driven by high parasympathetic tone, resulting in a reduction in visceral smooth muscle hyperactivity.

---

Ganglionic Blocking Effect

Butilehioscina also exhibits a concentration-dependent, weaker affinity for nicotinic receptors located in the autonomic ganglia embedded within the visceral wall. This engagement can lead to a minor ganglion-blocking effect that contributes to the overall attenuation of smooth muscle tone and modulation of excitatory pathway activity, leading to a state of reduced excitability within the targeted tissues.

The use of Butilhioscina (hyoscine butylbromide) is defined by its routes and administration forms, which include the oral tablet and the solution for injection. The approved routes are oral, and for the acute setting, intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection.

Official Dosing Regimens

For adult oral use, the standard dose is 20 mg per unit, taken up to four times daily. The parenteral dose is 20 mg, which may be repeated after a 30-minute interval if required, but the total daily intake from all routes must not exceed 100 mg. This establishes a divided daily frequency for oral use and an intermittent, as-needed schedule for the injection.

Procedural and Age-Specific Instructions

Tablets should be taken whole with water and are permitted regardless of food intake. Procedural requirements include giving IV injections slowly and avoiding the IM route in patients receiving anticoagulants.

For pediatric patients, different rules apply: children over 6 years have a fixed oral dose of 10 mg three times daily, while parenteral administration in infants and younger children is based on a weight-adjusted dosage. Standard clinical protocol limits the medicine to short-term use for acute episodes, advising against continuous daily administration without comprehensive re-evaluation.

Research Evidence / Overview of Studies for Butilhioscina

The research surrounding butilhioscina was studied for its application in conditions involving spasms and cramping, which are outcomes related to physical discomfort. Clinical evaluation has involved randomized controlled trials (RCTs) and systematic reviews, with findings helping contextualize how patients reported their experience during defined study intervals.

---

Evidence for Acute Gastrointestinal Spasms

Research has explored its use during periods of increased symptom activity, primarily examining short-term outcomes related to physical discomfort in adults and children (typically aged 8 years and older). Study designs often compared the medication to a placebo or to common pain relievers. The research highlights measurements taken during these studies; however, findings were mixed in some comparative trials. For instance, some data related to pain reduction in adults with acute gastroenteritis did not show a distinct pattern from those of the placebo group.

---

Evidence for Visceral Spasms in Specific Conditions

Studies explored the use of butilhioscina in conditions associated with acute or disruptive episodes, such as Irritable Bowel Syndrome (IBS) and colic. Systematic reviews have examined antispasmodic agents, describing patterns related to global symptom change and physical discomfort in the observed populations. The evidence quality varies across studies, and comparative evidence is lacking against other relevant therapies.

---

Research on Use in Diagnostic and Procedural Settings

Studies have also evaluated the medication in settings where temporary physiological imbalance needs to be addressed to achieve a technical aim, such as during endoscopy and advanced radiological imaging. Research describes patterns where changes in muscle contraction were observed, which helped contextualize how procedures evolved in the observed settings. The outcomes monitored were technical, focusing on the duration of reduced muscle movement.

---

Evidence Gaps and Uncertainties

Key limitations noted in scientific reviews include the prevalence of short follow-up durations in acute care settings, where limited information for long-term outcomes exists. Furthermore, data for very young children (under the age of 6 years) remain insufficient, as high-quality RCTs are still emerging for this group. The research provides context but does not determine whether an individual will respond similarly.

Common questions about Butilhioscina (FAQ)

---

Q: Is Butilhioscina the same as Buscopan?

Butilhioscina is the name of the active medicinal ingredient, which is also commonly referred to as hyoscine butylbromide. Buscopan is a widely known brand name under which hyoscine butylbromide is marketed and sold in various regions. Official documents use the active ingredient name when describing the medicine’s properties and regulatory information.

---

Q: How quickly does Butilhioscina start to work?

According to the official product information, the drug is rapidly absorbed by the body's tissues. The onset of action is generally quick, especially with injectable formulations. The clinical effects of the oral tablet formulation are generally reported to be noted within 15 to 30 minutes.

---

Q: How long do the effects of Butilhioscina usually last?

The duration of the main clinical effects of the medicine is generally reported as being around 4 to 6 hours. This reported duration provides context for its frequency of use, which is typically on an as-needed basis.

---

Q: Can Butilhioscina be used for pain other than abdominal cramps?

Official indications for Butilhioscina extend to the relief of spasm in the gastrointestinal, biliary, and urinary tracts. Therefore, it is used for spasms originating in these visceral organs. Official documents also describe its use as an aid in certain diagnostic procedures, such as radiology.

---

Q: What is the difference between Butilhioscina and a general pain reliever like ibuprofen?

Butilhioscina is a spasmolytic drug, meaning its action is specifically to relax smooth muscle by blocking certain nerve signals (acetylcholine). General pain relievers, such as ibuprofen, work through a different mechanism by blocking the production of pain and inflammation signals. This difference means the medicines address discomfort through distinct functional pathways in the body.

---

Q: Are there any long-term side effects associated with Butilhioscina use?

The medicine is generally intended for short-term use to manage acute episodes of spasm. Regulatory documents advise against continuous daily use without a medical re-evaluation. Research studies reviewed by official agencies often focus on short-term outcomes, and information on long-term safety data is noted to be limited.

---

Q: Can older people use Butilhioscina safely?

Official information indicates that no specific dose adjustment is typically required for older adults using the oral form. However, caution is advised as older individuals may be more susceptible to anticholinergic side effects, such as dry mouth or difficulty passing urine. Information regarding pre-existing conditions and the suitability of this medicine is found in the full regulatory documents.

---

Q: Are there any known food or drink restrictions when using Butilhioscina?

The tablets can be taken with or without food. However, official warnings specifically advise against the co-use of alcohol while using Butilhioscina. This is because combining the two may increase the reported risk of certain side effects, such as drowsiness.

---

Q: What are the official approvals or indications for Butilhioscina?

According to official regulatory documents, Butilhioscina is approved for the relief of spasms—or involuntary muscle contractions—in the smooth muscles of the gastrointestinal tract, the biliary tract (gallbladder and ducts), and the genitourinary tract (urinary system). It is also approved for use as an aid in certain diagnostic and endoscopic procedures.

---

Q: What happens if I miss a dose of Butilhioscina?

If a dose of the oral tablets is missed, general guidance in official patient information is to take the next dose at the usual scheduled time. Official guidance states that a double dose should not be taken to make up for a forgotten dose.

---

Q: What should I do if I think I've taken too much Butilhioscina?

Symptoms of taking too much Butilhioscina may include anticholinergic effects such as dry mouth, difficulty passing urine, or a rapid heart rate. Official regulatory documents stress that in the event of any suspected overdose, urgent medical attention is required in this circumstance.

---

Q: Does Butilhioscina interact with birth control pills?

Official regulatory guidelines on drug interactions do not document any specific interactions between Butilhioscina (hyoscine butylbromide) and hormonal birth control pills. The medicine’s primary action is localized within the smooth muscle of the abdominal organs.

---

Q: Is Butilhioscina addictive?

Butilhioscina is an antimuscarinic agent and is not classified as a controlled substance by major regulatory bodies. Official labeling and warnings for the drug do not contain information related to dependence or addiction potential.

---

Q: Does Butilhioscina contain gluten or lactose?

Official information confirms that some tablet formulations contain lactose as an inactive ingredient, or excipient. Information regarding excipients is available in the official Patient Information Leaflets. Gluten is generally not listed as a component.

---

Q: Does Butilhioscina affect driving ability?

Official warnings advise that Butilhioscina can cause temporary side effects such as blurred vision or dizziness. If these effects are experienced, it is advised that driving or operating machinery be avoided until symptoms resolve.

---

Q: Does Butilhioscina cause constipation?

Official product information lists constipation as a potential adverse reaction of Butilhioscina. This effect is a reflection of the drug's mechanism, which involves reducing the activity and motility of the gastrointestinal tract.

---

Q: Does Butilhioscina work for period pain?

The medicine is officially indicated for the relief of spasms in the female genitourinary tract. This general indication includes the relief of pain associated with spasms of the uterus, which can be a component of painful periods (dysmenorrhea).

---

Q: What is the shelf life of Butilhioscina tablets?

Official stability data for the tablets typically establishes the shelf life as 24 months from the date of manufacture. This shelf life is valid only when the product is stored correctly, generally below 25 C and kept in the original, protective packaging.

---

Q: Does Butilhioscina cause drowsiness or make you sleepy?

Drowsiness (somnolence) and feeling sleepy are listed in official documents as potential side effects. Regulatory warnings state that driving or operating machinery should be avoided if affected by these symptoms.

---

Q: Is Butilhioscina available over-the-counter (OTC) in some regions?

The regulatory status of Butilhioscina varies globally. While the injectable form is generally prescription-only, the oral tablet formulation is frequently available for purchase over-the-counter (OTC) without a prescription in many regions, depending on local regulations.

Butilhioscina (hyoscine butylbromide) must be stored and handled according to specific conditions defined in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Dosage Form	Mandatory Conditions
Tablets	Store below 25 C or 30 C; must be kept in the original package to protect from light and moisture.
Injection Solution	Store below 30 C in the outer carton for light protection. Solution is for single use only and must be used immediately after opening.

The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Butilhioscina must not be thrown away via wastewater or household waste. Disposal must be handled in accordance with local pharmaceutical waste requirements; patients are directed to ask a pharmacist for the proper disposal procedure.